peroxisome proliferator-activated receptor delta

Protease-Activated Receptor-4 diTFA 是蛋白酶激活受体 4 (PAR4) 激动剂。

Protease-Activated Receptor-1, PAR-1 Agonist acetate 是一种选择性蛋白酶激活受体 1 (PAR-1) 激动剂肽。 它对应于 PAR1 栓系配体，可以选择性地模拟凝血酶通过该受体的作用。

Protease-Activated Receptor-2, amide (SLIGKV-NH2) 是 PAR2 的激动剂，IC50为 10.4 M。

Bocidelpar 是一种有效的过氧化物酶体增殖物激活受体 delta 调节剂，可改善杜兴肌营养不良肌肉细胞中的线粒体生物合成和功能。

Protease-Activated Receptor-1 (PAR-1) Agonist TFA is a selective peptide that acts as an agonist for the proteinase-activated receptor-1 (PAR-1). Corresponding to the tethered ligand of PAR-1, this compound mimics the actions of thrombin through the PAR-1 receptor[1][2].

Protease-Activated Receptor-1 antagonist 2 是一种选择性蛋白酶激活受体-1 (PAR-1) 拮抗剂，口服活性，IC50值为7 nM。该化合物具有优良的药代动力学特性，适用于心血管疾病 (CVD) 如动脉粥样硬化和再狭窄的研究。

Protease-Activated Receptor-4 是蛋白酶激活受体 4 激动剂，具有抗血小板治疗。

Protease-Activated Receptor-1 antagonist 3 是蛋白酶激活受体 1protease-activated receptor-1 的有效拮抗剂 (IC50: 7 nM)。Protease-Activated Receptor-1 antagonist 3 与 hERG K+通道表现出结合亲和力 (IC50: 9 μM)。

TFRGAP-amide, human PAR-3-derived tethered ligand sequence which does not activate PAR-3 but rather activates PAR-1 and PAR-2, either in Jurkat or in other PAR-expressing cells.

Protease-Activated Receptor-3 (PAR-3) (1-6), human TFA is a peptide that acts as an agonist for the proteinase-activated receptor (PAR-3)[1].

Protease-Activated Receptor-1 antagonist 1 (Compound 13) 是一种蛋白酶激活受体 1 (PAR-1) 拮抗剂，通过 FLIPR 技术得到的 IC50 为 3 nM。Protease-Activated Receptor-1 antagonist 1 能够用于研究血栓性心血管、心肌梗塞和外周动脉疾病。

Protease-Activated Receptor-1 antagonist 2 是一种选择性的、口服具有活力的蛋白酶激活受体-1 (PAR-1) 拮抗剂 (IC50: 7 nM)。Protease-Activated Receptor-1 antagonist 2 显示出良好的药代动力学特性，能够用于进行心血管疾病 (CVD) 的相关研究（如动脉粥样硬化和再狭窄）。

Protease-Activated Receptor-1 (PAR-1) Agonist, a selective peptide, activates the PAR-1 receptor by mimicking the specific actions of thrombin. It corresponds to the PAR1 tethered ligand, facilitating selective activation of this receptor.

MBX-8025 is an agonist of peroxisome proliferator-activated receptor δ (PPARδ).1 It is greater than 750- and 2,500-fold selective for PPARδ over PPARα and PPARγ. MBX-8025 (10 mg/kg per day for eight weeks) reduces increases in fasting blood glucose and serum insulin levels, and decreases insulin resistance in Alms1 mutant (foz/foz) mice fed an atherogenic diet as a model of diet-induced obesity, type 2 diabetes, and non-alcoholic steatohepatitis (NASH).2 It also decreases serum alanine transaminase (ALT), as well as serum and hepatic cholesterol and triglyceride, levels and reduces markers of NASH in the same model. |1. Bays, H.E., Schwartz, S., Littlejohn, T., 3rd, et al. MBX-8025, a novel peroxisome proliferator receptor-δ agonist: Lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin. J. Clin. Endocrinol. Metab. 96(9), 2889-2897 (2011).|2. Haczeyni, F., Wang, H., Barn, V., et al. The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice. Hepatol. Commun. 1(7), 663-674 (2017).

KD-3010 is a peroxisome proliferator-activated receptor delta agonist potentially for the treatment of diabetes and obesity. KD-3010 dramatically ameliorates liver injury induced by carbon tetrachloride (CCl(4)) injections. Deposition of extracellular matrix proteins was lower in the KD3010-treated group than in the vehicle- or GW501516-treated group. Interestingly, profibrogenic connective tissue growth factor was induced significantly by GW501516, but not by KD-3010, following CCl(4) treatment.